Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Makers Rush to Apply for Anthrax as Additional Indication
November 19, 2001
- BI's Equity Stake in SSP exceeds 50%
November 12, 2001
- NEW PRODUCTS NEWS IN BRIEF
November 12, 2001
- Similar Function Comparison Method for Medical Materials Proposed
November 12, 2001
- AstraZeneca to Increase Share in Japan to 1.7% at End of 2001: CE McKillop
November 12, 2001
- Terumo Licenses New APD System from Debiotech of Spain
November 12, 2001
- BUSINESS NEWS IN BRIEF
November 12, 2001
- GL for Global Drug Development Needed: JPMA Expert
November 12, 2001
- Makers Providing More Products in Small Packages: Yano Report
November 12, 2001
- Approval Process for Medical Devices to Be Reviewed
November 12, 2001
- Sankyo Receives Approvable Letter for CS-866 from US FDA
November 12, 2001
- Fresenius: New APD System "sleep・safe"
November 12, 2001
- Sumitomo's Half-year Sales Top \69.2 Bil., Up \9 Bil.: President Yokotsuka
November 12, 2001
- GEMS Targeting Double-Digit Growth in Japanese Market: President Hogan
November 12, 2001
- EFPIA-EBC Position Statement: Japan（2）
November 12, 2001
- JACDS to Hold Self-medication Summit
November 12, 2001
- EFPIA-EBC Position Statement: Japan（1）
November 12, 2001
- Comprehensive Research Necessary in Psychiatry: Seminar
November 12, 2001
- ARB Effective for Heart Failure: Novartis Lecture
November 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…